Company Search:
Advanced Search
Sponsored Links
Celyad Oncology SA Company Snapshot
Celyad Oncology SA, formerly Celyad SA is a Belgium-based company. The Company is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The Company's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). It also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).

Sales Analysis. During the year ended December of 2020, sales at Celyad Oncology SA were 5,000.00 Euro (US$5.85 thousand). This is a decrease of 16.7% versus 2019, when the company's sales were 6,000.00 Euro.
Company ReportsSubscriptions
Looking For More?
Purchace an In-Depth Report
Celyad Oncology SA
  Stock Performance Chart for Celyad Oncology SA
  Stock Data: Recent Stock Performance:
  Current Price (9/24/2021): 3.70
(Figures in Euros )
1 Week -0.4%   13 Weeks 2.8%  
4 Weeks -18.1%   52 Weeks -52.8%  
Celyad Oncology SA Key Data:
  Ticker: CYAD Country: Belgium
  Exchanges: BRU Major Industry: Health Care Equipment & Services
    Sub Industry: Health & Allied Services
  2020 Sales 5,000
(Year Ending Jan 2021).
Employees: 82
  Currency: Euros Market Cap: 57,327,637
  Fiscal Yr Ends: December Shares Outstanding: 15,493,956
  Share Type: Actions Ordinaires Closely Held Shares: 3,271,516
Sponsored Links
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.